PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Storm Doses First Patient with Solid Tumour Drug Candidate

A candidate is the first molecule targeting an RNA methyltransferase enzyme to enter development.
Storm – a company focusing on the development of novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases – has announced that its first patient has been dosed with STC-15.
The candidate is an orally bioavailable METTL3 inhibitor and the first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development. The phase 1 study is a multiple ascending dose escalation trial aiming to enrol 40-60 patients to determine safety, pharmacokinetics, engagement, and biomarkers related to the mechanism and anti-tumour efficacy in patients with solid tumours.
Before the research, activity was demonstrated with STC-15 through direct cytotoxic and anti-cancer immune response mechanisms in both solid tumour and leukaemia models. The data indicated enhanced interferon signalling and synergy with T-cell checkpoint blockade as a pivotal STC-15 action. This ultimately resulted in anti-cancer immunity and tumour regression in rodent models.
Josefin-Beate Holz, chief medical officer at Storm, commented: “I am delighted with the successful initiation of STORM’s first candidate into the clinic from our innovative and proprietary pipeline. Clinical development allows us to establish meaningful clinical benefits with RNA-modifying enzyme inhibitors in cancer patients. This first trial is a ground-breaking milestone for the drug class, and we are looking forward to receiving the emerging data from the study.”
Dr Jerry McMahon, chief executive officer of Storm, added: “This is a major milestone for STORM as we enter clinical development with our lead candidate STC-15 and continue progressing a pipeline targeting RNA modifying enzymes beyond METTL3.
“We intend to exhibit preclinical data related to STC-15 at future medical conferences this year as we execute our phase 1 study in patients with solid tumours. We anticipate presenting results from our phase 1 study in 2023,” he concluded.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026